On March 28, CURLIM took part in the CMT France 2026 Congress, held at the University of Medicine in Lille and dedicated to the theme: “Living with CMT: towards better well-being.” The event brought together over 200 participants : patients,…
A new week, and another major achievement for CURLIM ! A few weeks ago, we announced our Orphan Drug Designation in Europe, and today, we’re proud to share that CURLIM has also obtained Orphan Drug Designation in the United States.…
We are proud to announce that CURLIM has been awarded as part of the 2024–2025 State Innovation Challenge, joining 147 projects supported by the French government under #France2030. This recognition marks a major milestone for CURLIM It reflects our determination…
We are pleased to announce that the European Commission, following a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has granted CLM001 orphan drug designation for the treatment of Charcot-Marie-Tooth disease (CMT).…